Abstract:Background A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Methods Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. Findings A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Interpretation Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile. A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile.

[Therapeutic Effect of Clofarabine in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia].

FLAG Regimen in Treatment of Relapsed/refractory Acute Leukemia

Single Arm, Multi-Center, Phase Ii Study Of Clofarabine In Chinese Pediatric Patients With Refractory Or Relapsed Acute Lymphoblastic Leukemia

OP0003 Single arm, multicentre, phase 2 study of clofarabine in Chinese paediatric patients with refractory or relapsed acute lymphoblastic leukaemia

Efficacy, Safety and Pharmacokinetics of Clofarabine in Chinese Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia: a Phase II, Multi-Center Study

Clinical observation of fiudarabine, cytarabine and granulocytecolony-stimulating factor regime in the treatment of children with refractory and relapsed acute leukemia

Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study

Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL

Clinical study of FLAG regimen for children with relapsed or refractory acute leukemia

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis

Efficacy of FLAG regimen in treatment of refractory acute leukemia in children

Decitabine Combined with Low-Dose Chemotherapy is Effective in the Treatment of Pediatric Refractory/Relapsed Acute Myeloid Leukemia

FLAG regimen in the treatment of refractory or relapsed adult acute lymphoblastic leukemia

Fludarabine combined with colony-stimulating factor and cytarabine regimen for treatment of refractory or relapsed acute myeloid leukemia

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy

Efficacy of Decitabine Combined with Low Dose Chemotherapy on Children with Acute Myeloid Leukemia

Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation

Treatment of Refractory and Relapsed Acute Lymphocytic Leukemia in Adults

Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group

Recurrent and Refractory Langerhans Cell Histiocytosis in Chil-dren Treated with the Combination of Cladribine and Cytarabine

Efficacy and Safety of Children with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.